Study Title: A Phase 1/2, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of SNDX-5613 in Combination with Intensive Chemotherapy in Participants with Newly Diagnosed Acute Myeloid Leukemias Harboring Alterations in Lysine-specific Methyltransferase 2A (KMT2A/MLL), Nucleophosmin 1 (NPM1), and Nucleoporin 98 (NUP98) Genes
For more information about the trial above please contact the study team:Medical University of South CarolinaPrincipal Investigator, Praneeth Baratam, at baratamp@musc.edu.Study Coordinator, Hana Baker, at bakerhan@musc.edu.Trial opened at the following institutions: Medical University of South Carolina